Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GRI Bio ( (GRI) ) has shared an announcement.
On January 21, 2026, GRI Bio, Inc. announced that its board and stockholders had approved a 1-for-28 reverse stock split of its common stock, following a special meeting held on January 15, 2026. The reverse split will take legal effect at 4:01 p.m. Eastern Time on January 23, 2026, with the stock expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker “GRI” and a new CUSIP number on January 26, 2026. The move will reduce the number of outstanding common shares from approximately 15.0 million to about 536,000 without changing the total authorized share count, and will include proportional adjustments to outstanding options, warrants, convertible securities and equity incentive plans, while cash will be paid in lieu of fractional shares. The company stated that the reverse split is intended to increase its per-share trading price and help it regain compliance with Nasdaq’s minimum bid price requirement, a step that could prove pivotal for maintaining its listing and access to public capital markets, with operational mechanics arranged so that most shareholders will not need to take any action as positions are automatically adjusted by brokers and the transfer agent.
The most recent analyst rating on (GRI) stock is a Hold with a $0.21 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn) and bearish technical trend/momentum. Valuation is constrained by unprofitable earnings and no dividend support. Offsetting these risks, recent corporate updates (positive Phase 2a data and new financing) provide incremental support but do not overcome the current financial and trend weakness.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio, Inc. is a clinical-stage biotechnology company focused on developing immune cell modulators to treat inflammatory, fibrotic and autoimmune diseases. Its therapies target Natural Killer T cells, particularly Type I invariant NKT cells, to interrupt disease progression and restore immune homeostasis, with lead candidate GRI-0621 in development as an oral treatment for idiopathic pulmonary fibrosis and additional programs aimed at systemic lupus erythematosus supported by a proprietary library of more than 500 compounds.
Average Trading Volume: 2,199,905
Technical Sentiment Signal: Sell
Current Market Cap: $3.1M
See more insights into GRI stock on TipRanks’ Stock Analysis page.